These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6099208)

  • 1. [Desensitization to VIP by down regulation of its peptide receptors in transformed HT-29 cells of human colonic epithelium in culture].
    Boissard C; Hejblum G; Marie JC; Gespach C; Rosselin G
    C R Acad Sci III; 1984; 299(19):795-8. PubMed ID: 6099208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal peptide receptor regulation and reversible desensitization in human colonic carcinoma cells in culture.
    Boissard C; Marie JC; Hejblum G; Gespach C; Rosselin G
    Cancer Res; 1986 Sep; 46(9):4406-13. PubMed ID: 3015387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined ultrastructural and biochemical study of cellular processing of vasoactive intestinal peptide and its receptors in human colonic carcinoma cells in culture.
    Hejblum G; Gali P; Boissard C; Astesano A; Marie JC; Anteunis A; Hui Bon Hoa D; Rosselin G
    Cancer Res; 1988 Nov; 48(21):6201-10. PubMed ID: 2844402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB; Niewiadomski P; Nowak JZ
    Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin inhibits vasoactive intestinal peptide (VIP) binding and VIP-induced cAMP accumulation into two human cancerous cell lines.
    Bellan C; Pic P; Marvaldi J; Fantini J; Pichon J
    Second Messengers Phosphoproteins; 1991; 13(4):163-71. PubMed ID: 1667418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor.
    Xia M; Sreedharan SP; Bolin DR; Gaufo GO; Goetzl EJ
    J Pharmacol Exp Ther; 1997 May; 281(2):629-33. PubMed ID: 9152366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of vasoactive intestinal peptide receptors in human colonic epithelial cells.
    Broyart JP; Dupont C; Laburthe M; Rosselin G
    J Clin Endocrinol Metab; 1981 Apr; 52(4):715-21. PubMed ID: 6259191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations of the VIP-stimulated cAMP pathway in rat distal colon after abdominal irradiation.
    Morel E; Dublineau I; Lebrun F; Griffiths NM
    Am J Physiol Gastrointest Liver Physiol; 2002 May; 282(5):G835-43. PubMed ID: 11960780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
    Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
    Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells.
    Hohmann EL; Tashjian AH
    Endocrinology; 1984 Apr; 114(4):1321-7. PubMed ID: 6323142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line, HT-29.
    Couvineau A; Rousset M; Laburthe M
    Biochem J; 1985 Oct; 231(1):139-43. PubMed ID: 2998337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
    Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
    Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
    Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
    Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.
    Laburthe M; Rousset M; Chevalier G; Boissard C; Dupont C; Zweibaum A; Rosselin G
    Cancer Res; 1980 Jul; 40(7):2529-33. PubMed ID: 6248206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity.
    Gespach C; Emami S; Rosselin G
    Biochem Biophys Res Commun; 1984 Apr; 120(2):641-9. PubMed ID: 6329177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages.
    Sokolowska P; Nowak JZ
    Ann N Y Acad Sci; 2006 Jul; 1070():566-9. PubMed ID: 16888226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.